News
Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF
On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the determination of the amount and conditions of reimbursement from health insurance for a drug containing micronized diosmin. The reimbursement is valid from March 1, 2022.
Metamizole, even after 100 years on the market, remains an important component of postoperative pain therapy
Metamizole has been used in the therapy of a wide range of acute and chronic pains for 100 years.…
Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility
Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory…
Even in Severe Cases of HAE, Individualized Treatment is Crucial – Case Study
As part of the case seminar from the HAExpert series, held on December 1, 2021, which specifically…
Orally Administered Berotralstat in the Prevention of Hereditary Angioedema Attacks
Berotralstat is an oral medication administered once daily, developed to prevent hereditary…
Current (and Future) Possibilities for Diagnosing Alpha-1-Antitrypsin Deficiency
Alpha-1-antitrypsin deficiency (AAT) is associated, among other things, with the development of…
How and What the National AATD Register Benefits Experts and Patients
Given that alpha-1-antitrypsin deficiency (AATD) is still not receiving enough attention, it is…
How and How the Czech National Hemophilia Program Benefits Professionals and Patients
The Czech National Hemophilia Program (ČNHP) has been an interdisciplinary initiative for many…
Analgesic Effects of Using Ringer's Solution in Wound Healing Management
Pain resulting from skin defects of various etiologies causes significant discomfort for the…
Wound Treatment Without Pain? A Rinse Solution Can Help
Patients dealing with a healing wound may fear painful dressing changes. The wound bed is exposed…